

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

176

In Re Application Of: Nikolich et al.

JUL 23 2007

AMERICAN
TRADE
MARK
OFFICE

WS

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/733,691	12/11/03	not known	000041022	1645 1655	9351

Title: Immunogenic Compositions Including Rough Phenotype Brucella Host Strains and Complementaion DNA Fragment

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

07/24/2007 MAHME01 00000159 210380 10733691

01 FC:1806 180.00 DA

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.
176

In Re Application of: **Nikolich et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/733,691	12/11/03	not known	000041022	1653	9351

Title: Immunogenic Compositions Including Rough Phenotype Brucella Host Strains and Complementaion DNA Fragment

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below.

Charge the amount of \$180.00

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Signature

Marlana Titus, Reg. No. 35,843

for **Elizabeth Arwine, Esq., Reg. No 35,865**
U.S. Army Medical Research and Materiel
Command
504 Scott Street
Ft. Detrick, MD 21702-5012

801 977 7227

cc:

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

Dated: **July 20, 2007**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of

NIKOLICH et al.

Group Art Unit: 1645

Application No. 10/733,691

Examiner: Navarro, M.

Priority claimed from: U.S. Provisional applications 60/433,164 (filed December 12, 2002), and 60/503,016 (filed September 15, 2003)

Filed: December 11, 2003

For: Immunogenic Compositions Including Rough Phenotype Brucella Host Strains and Complementation DNA Fragments

* * * * *

CERTIFICATE OF MAILING BY "FEDERAL EXPRESS"

I hereby certify that the following correspondence is being deposited with Federal Express in an envelope addressed to: The Commissioner for Patents, U.S. Patent and Trademark Office, 401 Dulany Street, Randolph Building, Mail Stop Amendment, Alexandria, VA 22313, on July 20, 2007:

- (1) Combined Amendment & Petition for Extension of Time (large entity) (2 pages, in duplicate)
- (2) Amendment (22 pages)
- (3) Transmittal of Information Disclosure Statement (2 pages, in duplicate)
- (4) PTO Form 1449 (2 pages)
- (5) Copies of 11 references
- (6) certificate of mailing by Federal Express (1 page)
- (7) postcard receipt listing all enclosed items

Federal Express
Tracking Number: 858010969256



Marlana K. Titus
Nash & Titus, LLC
Reg. No. 35,843
6005 Riggs Road
Laytonsville, MD 20882

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 23 2007

Docket Number (Optional)
Army176

Application Number

10/733,691

Applicant(s)
Nikolich et al.

Filing Date

12-11-03

Group Art Unit

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cloeckaert A, Grayon M, Verger JM, Letesson JJ, Godfroid F. Conservation of seven genes involved in the biosynthesis of the lipopolysaccharide O side chain in <i>Brucella</i> spp. <i>Res Microbiol.</i> 2000 Apr;151(3):209-16.
	Godfroid F, Cloeckaert A, Taminiau B, Danese I, Tibor A, de Bolle X, Mertens P, Letesson JJ. Genetic organisation of the lipopolysaccharide O-antigen biosynthesis region of <i>brucella melitensis</i> 16M (wbk). <i>Res Microbiol.</i> 2000 Oct;151(8):655-68.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional) Army176	Application Number 10/733,691
Applicant(s) Nikolich et al.	
Filing Date 12-11-03	Group Art Unit 1645

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Allen CA, Adams LG, Ficht TA. Transposon-derived <i>Brucella abortus</i> rough mutants are attenuated and exhibit reduced intracellular survival. <i>Infect Immun.</i> 1998 Mar;66(3):1008-16.
	Foulongne V, Bourg G, Cazevieille C, Michaux-Charachon S, O'Callaghan D. Identification of <i>Brucella suis</i> genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis. <i>Infect Immun.</i> 2000 Mar;68(3):1297-303.
	Godfroid F, Taminiac B, Danese I, Denoel P, Tibor A, Weynants V, Cloeckaert A, Godfroid J, Letesson JJ. Identification of the perosamine synthetase gene of <i>Brucella melitensis</i> 16M and involvement of lipopolysaccharide O side chain in <i>Brucella</i> survival in mice and in macrophages. <i>Infect Immun.</i> 1998 Nov;66(11):5485-93.
	Godfroid F, Cloeckaert A, Taminiac B, Danese I, Tibor A, de Bolle X, Mertens P, Letesson JJ. Genetic organisation of the lipopolysaccharide O-antigen biosynthesis region of <i>brucella melitensis</i> 16M (wbk). <i>Res Microbiol.</i> 2000 Oct;151(8):655-68.
	McQuiston JR, Vemulapalli R, Inzana TJ, Schurig GG, Sriranganathan N, Fritzinger D, Hadfield TL, Warren RA, Lindler LE, Snellings N, Hoover D, Halling SM, Boyle SM. Genetic characterization of a <i>Tn5</i> -disrupted glycosyltransferase gene homolog in <i>Brucella abortus</i> and its effect on lipopolysaccharide composition and virulence. <i>Infect Immun.</i> 1999 Aug;67(8):3830-5. Erratum in: <i>Infect Immun.</i> 2000 Sep;68(9):5471.
	Monreal D, Grillo MJ, Gonzalez D, Marin CM, De Miguel MJ, Lopez-Goni I, Blasco JM, Cloeckaert A, Moriyon I. Characterization of <i>Brucella abortus</i> O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against <i>Brucella abortus</i> and <i>Brucella ovis</i> in the mouse model. <i>Infect Immun.</i> 2003 Jun;71(6):3261-71.
	Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of <i>Brucella</i> by rough strain vaccines derived from <i>Brucella melitensis</i> and <i>Brucella suis</i> biovar 4. <i>Am J Vet Res.</i> 1996 May;57(5):677-83.
	Ugalde JE, Czibener C, Feldman MF, Ugalde RA. Identification and characterization of the <i>Brucella abortus</i> phosphoglucomutase gene: role of lipopolysaccharide in virulence and intracellular multiplication. <i>Infect Immun.</i> 2000 Oct;68(10):5716-23.
	Ugalde JE, Comerci DJ, Leguizamon MS, Ugalde RA. Evaluation of <i>Brucella abortus</i> phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. <i>Infect Immun.</i> 2003 Nov;71(11):6264-9.
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.